Detalles de la búsqueda
1.
Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis.
Gut Pathog
; 15(1): 14, 2023 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36945059
2.
Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.
Eur J Pharmacol
; 779: 168-76, 2016 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26980242
3.
Pharmacological properties and clinical findings of rifaximin (RIFXIMA® TABLETS 200â mg).
Nihon Yakurigaku Zasshi
; 149(6): 288-295, 2017.
Artículo
en Japonés
| MEDLINE | ID: mdl-28626122
4.
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
J Med Chem
; 53(21): 7549-63, 2010 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20931963
5.
Design and synthesis of piperazinylpyridine derivatives as novel 5-HT1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS).
Chem Pharm Bull (Tokyo)
; 57(1): 34-42, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19122313
6.
Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
J Pharmacol Exp Ther
; 322(3): 1315-23, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17540858
Resultados
1 -
6
de 6
1
Próxima >
>>